Please ensure Javascript is enabled for purposes of website accessibility
CORRESP

Dyne Therapeutics, Inc.

1560 Trapelo Road

Waltham, MA 02451

November 15, 2021

VIA EDGAR SUBMISSION

U.S. Securities and Exchange Commission

Division of Corporation Finance, Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Michael Davis

Re: Dyne Therapeutics, Inc.

Registration Statement on Form S-3

File No. 333-260755

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Dyne Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-260755), so that it may become effective at 4:00 p.m., Eastern time, on November 17, 2021, or as soon as practicable thereafter.

 

Very truly yours,
DYNE THERAPEUTICS, INC.
By:  

/s/ Joshua Brumm

  Name:   Joshua Brumm
  Title:   President and Chief Executive Officer